Mid-Term Feasibility of Percutaneous Left Atrial Appendage Occlusion in Elderly Patients with Non-Valvular Atrial Fibrillation

Overview

Journal J Clin Med

Specialty General Medicine

Date 2023 Sep 28

PMID 37762964

Authors

Nobuyuki Fukuda

Teruhiko Imamura

Shuhei Tanaka

Naoya Kataoka

Ryuichi Ushijima

Hiroshi Ueno

Koichiro Kinugawa

Affiliations

Soon will be listed here.

Abstract

Background: Percutaneous left atrial appendage occlusion (LAAO) therapy using the WATCHMAN system has been introduced to prevent thrombosis and minimize the use of anticoagulants in patients with non-valvular atrial fibrillation. Given the high risk of bleeding and stroke in elderly patients, these patients would be good candidates for this therapy. However, the efficacy and feasibility of LAAO therapy in elderly patients remains uncertain.

Methods: Consecutive patients who underwent LAAO therapy using the WATCHMAN system in a large academic center between June 2020 and March 2023 were included. The safety and efficacy of LAAO therapy during the 1-year observation period in patients aged ≥85 years old were compared with those in the younger cohort.

Results: A total of 188 patients (78.4 ± 6.9 years old, 133 male patients) were included. 34 patients were ≥85 years old, 96 were between 75 and 84 years old, and 58 were <75 years old. The elderly group had a higher CHADS-VASc score and were at greater risk of falling-related bleeding compared with the younger cohort. The device implantations were successful in all patients except for one. During the 1-year observation period, one patient had a peri-device leak >5 mm and there were 6 device-related cases of thrombosis, whose incidence was not significantly different between the groups ( = 0.98). The cumulative incidences of bleeding and thrombotic events in the elderly group were as low as in the younger cohort ( > 0.05 for both). Most anticoagulants were terminated regardless of age.

Conclusion: The mid-term feasibility and efficacy of percutaneous LAAO therapy using the WATCHMAN system in elderly patients aged ≥85 years were as acceptable as in the younger cohort.

Citing Articles

In-hospital safety outcomes of left atrial appendage occlusion in octogenarians and nonagenarians.

Ismayl M, Ahmed H, Goldsweig A, Freeman J, Alkhouli M Europace. 2024; 26(3).

PMID: 38391186 PMC: 10927254. DOI: 10.1093/europace/euae055.

References

Sellers M, Newby L . Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011; 161(2):241-6. DOI: 10.1016/j.ahj.2010.11.002. View

Boersma L, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B . Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017; 14(9):1302-1308. DOI: 10.1016/j.hrthm.2017.05.038. View

Yamashita Y, Hamatani Y, Esato M, Chun Y, Tsuji H, Wada H . Clinical Characteristics and Outcomes in Extreme Elderly (Age ≥ 85 Years) Japanese Patients With Atrial Fibrillation: The Fushimi AF Registry. Chest. 2015; 149(2):401-412. DOI: 10.1378/chest.15-1095. View

Yamashita T, Suzuki S, Inoue H, Akao M, Atarashi H, Ikeda T . Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry. Eur Heart J Qual Care Clin Outcomes. 2021; 8(2):202-213. PMC: 8888123. DOI: 10.1093/ehjqcco/qcab025. View

Fukuda N, Imamura T, Tanaka S, Kataoka N, Ushijima R, Ueno H . Comparison in Short-Term Safety and Efficacy between New-Generation WATCHMAN FLX and Conventional WATCHMAN 2.5 for Percutaneous Left Atrial Appendage Closure. J Clin Med. 2022; 11(6). PMC: 8949425. DOI: 10.3390/jcm11061618. View

Ono K, Iwasaki Y, Akao M, Ikeda T, Ishii K, Inden Y . JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Circ J. 2022; 86(11):1790-1924. DOI: 10.1253/circj.CJ-20-1212. View

Reddy V, Holmes D, Doshi S, Neuzil P, Kar S . Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation. 2011; 123(4):417-24. DOI: 10.1161/CIRCULATIONAHA.110.976449. View

Toda Kato E, Goto S, Giugliano R . Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. Ageing Res Rev. 2018; 49:115-124. DOI: 10.1016/j.arr.2018.10.006. View

Pearce L, Hart R, Halperin J . Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med. 2000; 109(1):45-51. DOI: 10.1016/s0002-9343(00)00440-x. View

10.

Holmes Jr D, Kar S, Price M, Whisenant B, Sievert H, Doshi S . Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014; 64(1):1-12. DOI: 10.1016/j.jacc.2014.04.029. View

11.

Kar S, Doshi S, Sadhu A, Horton R, Osorio J, Ellis C . Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial. Circulation. 2021; 143(18):1754-1762. DOI: 10.1161/CIRCULATIONAHA.120.050117. View

12.

Simard T, Jung R, Lehenbauer K, Piayda K, Pracon R, Jackson G . Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion. J Am Coll Cardiol. 2021; 78(4):297-313. DOI: 10.1016/j.jacc.2021.04.098. View

13.

Pisters R, Lane D, Nieuwlaat R, de Vos C, Crijns H, Lip G . A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010; 138(5):1093-100. DOI: 10.1378/chest.10-0134. View

14.

Ryuzaki S, Kondo Y, Nakano M, Nakano M, Kajiyama T, Ito R . Antithrombotic Regimen After Percutaneous Left Atrial Appendage Closure　- A Real-World Study. Circ J. 2023; 87(12):1820-1827. DOI: 10.1253/circj.CJ-22-0687. View

15.

Blackshear J, ODell J . Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996; 61(2):755-9. DOI: 10.1016/0003-4975(95)00887-X. View

16.

Holmes D, Reddy V, Turi Z, Doshi S, Sievert H, Buchbinder M . Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374(9689):534-42. DOI: 10.1016/S0140-6736(09)61343-X. View

17.

Price M, Slotwiner D, Du C, Freeman J, Turi Z, Rammohan C . Clinical Outcomes at 1 Year Following Transcatheter Left Atrial Appendage Occlusion in the United States. JACC Cardiovasc Interv. 2022; 15(7):741-750. PMC: 9116488. DOI: 10.1016/j.jcin.2022.02.009. View

18.

Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. DOI: 10.1056/NEJMoa1107039. View

19.

Nogami A, Kurita T, Kusano K, Goya M, Shoda M, Tada H . JCS/JHRS 2021 Guideline Focused Update on Non-Pharmacotherapy of Cardiac Arrhythmias. Circ J. 2022; 86(2):337-363. DOI: 10.1253/circj.CJ-21-0162. View

20.

Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. DOI: 10.1056/NEJMoa1310907. View